Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.

Stuss, Michal

Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis. [electronic resource] - The Journal of clinical endocrinology and metabolism May 2013 - E1007-11 p. digital

Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1945-7197

10.1210/jc.2012-3885 doi


Aged
Aged, 80 and over
Bone Density--drug effects
Bone Density Conservation Agents--therapeutic use
Calcium, Dietary--therapeutic use
Cholecalciferol--therapeutic use
Combined Modality Therapy
Dietary Supplements
Diphosphonates--therapeutic use
Female
Gene Expression Regulation--drug effects
Humans
Ibandronic Acid
Leukocytes, Mononuclear--drug effects
Middle Aged
Organometallic Compounds--therapeutic use
Osteoporosis, Postmenopausal--blood
Osteoprotegerin--blood
RANK Ligand--blood
RNA, Messenger--metabolism
Receptor Activator of Nuclear Factor-kappa B--blood
Thiophenes--therapeutic use